Short Interest in Bio-Path Holdings, Inc. (NASDAQ:BPTH) Drops By 80.0%

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 77,800 shares, a decline of 80.0% from the October 15th total of 388,600 shares. Based on an average daily trading volume, of 1,410,000 shares, the short-interest ratio is presently 0.1 days. Approximately 2.1% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Bio-Path in a report on Friday, November 8th. They set a “sell” rating for the company.

Bio-Path Price Performance

BPTH stock traded up $0.01 during trading on Wednesday, reaching $0.88. 3,283 shares of the company were exchanged, compared to its average volume of 1,149,348. The company has a 50-day moving average of $0.99 and a two-hundred day moving average of $1.61. Bio-Path has a twelve month low of $0.80 and a twelve month high of $12.40.

Bio-Path (NASDAQ:BPTH) last released its quarterly earnings data on Thursday, August 15th. The company reported ($1.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.38. During the same quarter in the prior year, the business earned ($10.60) earnings per share. Research analysts anticipate that Bio-Path will post -6.2 EPS for the current fiscal year.

Institutional Trading of Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent filing with the Securities and Exchange Commission (SEC). 5.74% of the stock is owned by institutional investors and hedge funds.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.